<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04233190</url>
  </required_header>
  <id_info>
    <org_study_id>EF162</org_study_id>
    <nct_id>NCT04233190</nct_id>
  </id_info>
  <brief_title>A Multicenter, Randomized, Parallel, Two-Period, Non-Inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment</brief_title>
  <official_title>A Randomized, Parallel-Group, Open, Two-Period, Comparative Non-Inferiority Study of Eurofarma's Formoterol/Budesonide vs Alenia in the Treatment of Moderate to Severe Persistent Asthma With and Without Chronic Obstructive Pulmonary COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eurofarma Laboratorios S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eurofarma Laboratorios S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase III study, multicenter, randomized, parallel, open, two-period, comparative&#xD;
      non-inferiority of Eurofarma versus Alenia® in the treatment of moderate to severe persistent&#xD;
      asthma with and without obstructive pulmonary disease (COPD)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the first study period (Period 1), patients with moderate to severe persistent asthma&#xD;
      according to GINA criteria, with or without COPD, will be randomized at a 1: 1 ratio to&#xD;
      receive formoterol 12mcg / budesonide 400mcg Eurofarma or Alenia® 12mcg / 400mcg during 12&#xD;
      weeks Participants who maintain asthma control at the end of this treatment period (no more&#xD;
      than one exacerbation during this period) will be included in Period 2, in which the dose of&#xD;
      each investigational product will be reduced (step-down), and the patients will receive&#xD;
      formoterol 6mcg / budesonide 200mcg Eurofarma or Alenia® 6mcg / 200mcg, respectively, for an&#xD;
      additional 12 weeks. The primary non-inferiority assessment will be performed at the end of&#xD;
      24 weeks of treatment, with intermediate assessment at the end of week 12.&#xD;
&#xD;
      The study will be conducted in an open label since the devices for inhalation of products&#xD;
      have different aspects, making it impossible to blind the treatments of the study. The&#xD;
      primary efficacy variable (forced expiratory volume in one second [FEV1]) minimizes the&#xD;
      potential bias arising from the open label of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 15, 2022</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In the first study period (Period 1), patients with moderate to severe persistent asthma according to GINA criteria, with or without COPD, will be randomized at a 1: 1 ratio to receive formoterol 12mcg / budesonide 400mcg Eurofarma or Alenia® 12mcg / 400mcg during 12 weeks Participants who maintain asthma control at the end of this treatment period (no more than one exacerbation during this period) will be included in Period 2, in which the dose of each investigational product will be reduced (step-down), and the patients will receive formoterol 6mcg / budesonide 200mcg Eurofarma or Alenia® 6mcg / 200mcg, respectively, for an additional 12 weeks. The primary non-inferiority assessment will be performed at the end of 24 weeks of treatment, with intermediate assessment at the end of week 12.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1</measure>
    <time_frame>24 weeks</time_frame>
    <description>Average change from baseline in pre-dose Forced Expiratory Volume in one second</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">472</enrollment>
  <condition>Asthma Copd</condition>
  <arm_group>
    <arm_group_label>Formoterol + budesonide Eurofarma (12/400mcg e 6/200mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formoterol 12mcg + budesonide 400mcg / Formoterol 6mcg + budesonide 200mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alenia® (12/400mcg e 6/200mcg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg</intervention_name>
    <description>one inhalation, twice daily</description>
    <arm_group_label>Alenia® (12/400mcg e 6/200mcg)</arm_group_label>
    <arm_group_label>Formoterol + budesonide Eurofarma (12/400mcg e 6/200mcg)</arm_group_label>
    <other_name>fumarato de formoterol di-hidratado 12mcg + budesonida 400mcg/fumarato de formoterol di-hidratado 62mcg + budesonida 200mcg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 12 years&#xD;
&#xD;
          -  Presence of moderate to severe persistent asthma according to Global Initiative for&#xD;
             Asthma (GINA) 1 criteria for at least 1 year, clinically stable (controlled) for at&#xD;
             least 30 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Occurrence of asthma exacerbation within 30 days prior to initiation of study&#xD;
             treatment.&#xD;
&#xD;
          -  Presence of acute or chronic symptomatic airway infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daniele Hamamoto</last_name>
    <phone>+55 11 50908417</phone>
    <email>daniele.hamamoto@eurofarma.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bruno Rosa</last_name>
    <phone>+55 11 50908481</phone>
    <email>bruno.bezerra@eurofarma.com.br</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

